Stealth Peptides Inc. Reports Successful Clinical Study of Oral Bendavia
1/22/2013 9:29:44 AM
More...
|
Stealth Peptides Inc. Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury
1/16/2013 9:30:59 AM
More...
|
Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia
4/9/2012 9:32:51 AM
More...
|
Stealth Peptides Inc. Release: Dr. Robert Kloner Presents Bendavia Research at 2011 American Heart Association Annual Meeting
11/28/2011 10:51:14 AM
More...
|
Stealth Peptides Inc. Release: Researchers Present Promising Bendavia Findings at Annual Stealth Peptides Inc. Meeting
11/15/2011 7:16:21 AM
More...
|
Stealth Peptides Inc. Release: Bendavia Presented at 2011 American Heart Association’s Cardiovascular Scientific Sessions
8/1/2011 8:26:03 AM
More...
|
Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study
6/27/2011 10:03:30 AM
More...
|
Stealth Peptides Inc.' Bendavia(TM) Recognized as One of Stealth Peptides Inc.'s Top 10 Cardiovascular and Metabolic Development Programs to Watch
11/8/2010 9:53:39 AM
More...
|
Stealth Peptides Inc. Announces Clinical Phase I Results With Bendavia(TM) Demonstrating Safety And Tolerability With Highly Predictable Pharmacokinetics
9/13/2010 9:28:17 AM
More...
|
Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with BendaviaTM, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury
6/14/2010 1:54:39 PM
More...
|
|